Market Outlook for Biosimilars - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Market Outlook for Biosimilars
The author reviews the major biopharmaceutical markets' activity and predicts how the markets may evolve.


Pharmaceutical Technology


References

1. P. Narang, Datamonitor Biosimilars Series 2008: Forecast Analysis (DMHC2477, Datamonitor, London, June 2009).

2. IMS Health, MIDAS sales data (Norwalk, CT, March 2009).

3. S.W. Schondelmeyer, L. Purvis, and D.J. Gross, Rx Watchdog Report: Trends in Manufacturer Prices of Specialty Prescription Drugs Used by Medicare Beneficiaries 2004 to 2007 (AARP Public Policy Institute, Washington, DC, 2008), http://assets.aarp.org/rgcenter/health/2008_15_specialty_q407.pdf, accessed March 2009.

4. S. Sutter, "US House Panel Adopts 12-Year Exclusivity," Scrip (3457), 1 (2009).

5. I. Schofield, "EC Defends Biosimilar Safety," Scrip (3358), 1 (2008).

6. I. Schofield, "Biosimilars Struggling with the Market," Scrip (3359–3360), 23 (2008).

7. Business Monitor International, "First Biosimilar Submitted for Approval," in BMI Industry Insights—Pharma and Healthcare, Asia (London, November 27, 2008).

8. W. Marth, remarks at Bank of America Securities Health Care Conference (Las Vegas, NV, 2008).

9. E.F. Licking, "Merck's Ambitious Plans for Follow-On Biologics," BioPharma Today (2008), http://www.biopharmatoday.com/2008/12/mercks-ambitious-plansfor-follow-on-biologics.html, accessed August 18, 2009.

10. A. Witty, remarks at Goldman Sachs CEOs Unscripted Healthcare Conference (New York, 2009).

11. T. Staton, "J&J Says 'Not Now' on Biosimilars" FiercePharma April 8, 2009, http://www.fiercepharma.com/story/j-j-says-not-now-biosimilars/2009-04-08, accessed August 20, 2009.

12. I. Schofield, "Biosimilars Regulation Finds Its Feet," Scrip (100), 63–64 (2008).

13. N. Faigen, "No End in Sight for Biosimilar Data Exclusivity Debate," Scrip Online (November 27, 2008), http://www.scripnews.com/policyregulation/No-end-in-sight-for-biosimilar-data-exclusivity-debate-9064?autnID=/contentstore/scripnews/codex/7f1db720-bc67-11dd-9174-39d0f0d8ae6e.xml, accessed August 20, 2009.

14. FDA, "US FDA Considerations: Discussion by National Regulatory Authorities with World Health Organization (WHO) on Possible International Non-Proprietary Name (INN) Policies for Biosimilars," (Center for Drug Evaluation and Research, Silver Spring, MD, 2006), http://www.fda.gov/cder/news/biosimilars.htm, accessed March 26, 2009.

15. S. King, "Big Pharma Turns to Biologics for Growth" (DMHC2190, Datamonitor, London, May 2006).

16. "Zenotech Builds Pipeline of 'Generic' Monoclonals," Scrip (3237), 10 (2007).

17. T. Ignjatovic, Biosimilars Series: Strategic Issues—Potential Remains Uncertain (DMHC2337, Datamonitor, London, October 2007).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here